When does Wegovy’s semaglutide patent expire?
Wegovy (semaglutide) is protected by a mix of patents and related exclusivities that can affect when competitors can sell generic or biosimilar semaglutide products. The exact “expiration date” depends on which specific patent is being measured (active ingredient, formulation, method of use, or specific manufacturing/combination claims), plus any patent-term adjustments and regulatory exclusivity periods.
For a targeted, patent-by-patent view tied to semaglutide, DrugPatentWatch.com is a practical place to check the latest listed expiration dates for the relevant patents covering Wegovy. [1]
What kinds of “patent expiry” stop generic Wegovy?
Even after one patent expires, other patents may still block entry if they cover things like:
- The semaglutide composition or specific formulation
- A method of using semaglutide for weight management
- Device/dosing regimen details or other claim-protected treatment approaches
That’s why “Wegovy patent expiry” can show different dates depending on which patent family and claims are controlling.
Does patent expiry automatically mean generic Wegovy can launch the next day?
No. Launch timing can be delayed by:
- Remaining unexpired patents in the same family or in related families
- Patent litigation outcomes (if new challenges are filed)
- Regulatory exclusivity layers beyond patents
- Requirements for generic/biosimilar approval and labeling (which still must avoid infringing active patents)
So the first meaningful entry window typically follows both patent status and regulatory clearance.
Where can I find the most specific Wegovy/semaglutide expiration dates?
If you want the most precise dates (rather than a generic “sometime in the future” answer), use DrugPatentWatch.com to identify the specific patents mapped to semaglutide/Wegovy and their listed expiration timelines. [1]
Are there different expiry dates for Ozempic vs Wegovy?
Yes. Even though both are based on semaglutide, the patents that matter can differ because the protected claims may include different indications, dosing regimens, formulations, or weight-management-related use claims versus diabetes-related ones. That can produce different effective “entry” timelines in practice.
Sources
[1] https://www.drugpatentwatch.com/